Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer's Disease Research at CTAD Conference

Eisai is scheduled to present new five-year treatment data for lecanemab (LEQEMBI®), its anti-amyloid beta protofibril antibody for Alzheimer's disease, at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The presentation will include findings from the Clarity AD long-term study, real-world data from the LEADER study, and research on safety, biomarkers, and Alzheimer's disease-related co-pathology.